September 22-25, 2020

Working together today for a better tomorrow

From its 2005 inception at the National Institutes of Health in Bethesda, Maryland, USA, the International Symposium on Pheochromocytoma has gathered internationally prominent clinicians and scientists in order to foster cross-continental partnerships. Under the auspices of the Pheochromocytoma and Research and Support Organization (PRESSOR), worldwide experts have convened in Cambridge, England, Paris, France, Kyoto, Japan, and Sydney, Australia to present, discuss, and explore therapeutic options, novel genetic and metabolomic approaches, diagnostic imaging, translational research efforts and much more. This time, the leading worldwide experts in basic, clinical, and translational pheochromocytoma research will be welcomed by Charles University in Prague, Czech Republic, one of the oldest universities in the world. Located in the center of Prague, this venue will offer a unique and unmatched European atmosphere and culture. Leading experts in the field of pheochromocytoma will present their latest discoveries, guidelines, clinical trials results, collaborative efforts, and future visions for studying this tumor. Four plenary sessions will focus on the latest discoveries and perspectives in genetics and epigenetics, biochemistry and metabologenomics, theranostics, and mitochondrial function. The symposium welcomes patients and will have several sessions devoted to patient management, including unique case presentations and in-person discussions with expert physicians on their approach to the workup, diagnosis, and treatment of patients with this tumor. All health care professionals, scientists, students, patients, and allies are welcome to attend this Symposium, which will undoubtedly outline new focuses and avenues for early diagnosis, treatment, and ultimately prevention of pheochromocytoma. Only through spreading the word “pheochromocytoma” can we beat this tumor.

Copyright © 2013 Galén Symposion, All Rights Reserved
web-mastering People For Net a.s.